Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint.

Slides:

Advertisements

Similar presentations

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New.

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study Marco Lo Iacono, PhD, Valentina.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer Chao Li, MD, PhD,

P63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue Marco Lo Iacono, PhD, Valentina Monica,

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer Hui Yu, MD, PhD, Cory Batenchuk, PhD,

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

An Unusual Metastatic Site for Primary Lung Cancer: The Spleen

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities Matthew P. Humphries, PhD, Stephen.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme Antonio.

“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy Kentaro Ito, MD, Osamu Hataji, MD, Koji Katsuta, MD, Tetsu Kobayashi,

Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the.

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer Antonio Calles, MD, Xiaoyun Liao, MD,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Activity of Gefitinib in a Non–Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations Alessandro Morabito, MD, Raffaele Costanzo,

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors Sophie Feng, M.B.B.S., Jermaine Coward, PhD,

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Mitotic Inhibitors Journal of Thoracic Oncology

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga, MD, PhD, Emine Bozkurtlar,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

It’s All in the “Swerve of the Curve”

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer Nicola Normanno, MD, Carmine.

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle

Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma Iris C. Salaroglio, PhD, Joanna Kopecka, PhD, Francesca.

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors Antonio Marchetti, MD, PhD, Massimo Barberis, MD, Renato Franco, MD, Graziano De Luca, MD, Maria Vittoria Pace, PhD, Stefania Staibano, MD, Marco Volante, MD, Fiamma Buttitta, MD, PhD, Elena Guerini-Rocco, MD, Luisella Righi, MD, Tommaso D’antuono, BTech, Giorgio V. Scagliotti, MD, Carmine Pinto, MD, Gaetano De Rosa, MD, Mauro Papotti, MD Journal of Thoracic Oncology Volume 12, Issue 11, Pages 1654-1663 (November 2017) DOI: 10.1016/j.jtho.2017.07.031 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 A typical example of immunohistochemical staining with the programmed death ligand 1 immunohistochemical 22C3 pharmDx test (Agilent) on the Dako Autostainer (A) and the in vitro diagnostics Ventana programmed death ligand 1 (SP263) test on the on the Ventana BenchMark platform (C) is reported. Note that at a low magnification (×100) (A and C), the percentage of positive tumor cells with the SP263 clone seems to be higher owing to the slightly higher intensity of the staining. However, at higher magnification (×200–400), if a weak and incomplete cell membrane staining is considered according to the manufacturer recommendations, the two tests show a very similar percentage of immunoreactive tumor cells (magnified frames B and D). Journal of Thoracic Oncology 2017 12, 1654-1663DOI: (10.1016/j.jtho.2017.07.031) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Dot-and-line diagram of the distribution and correlation of programmed death ligand 1 (PD-L1) expression levels detected by the PD-L1 immunohistochemistry (IHC) 22C3 pharmDx test (Agilent), on the Dako Autostainer (top) and the in vitro diagnostics Ventana PD-L1 (SP263) test on the Ventana BenchMark platform (bottom) in each of the four referral pathology centers. Data are often superimposed, mainly for cases with low PD-L1 expression levels. Journal of Thoracic Oncology 2017 12, 1654-1663DOI: (10.1016/j.jtho.2017.07.031) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Scatter diagrams illustrating the correlation between the programmed death ligand 1 immunohistochemical 22C3 pharmDx test (22C3) and in vitro diagnostics Ventana programmed death ligand 1 (SP263) expression levels in each of the four centers. See the text for details. Journal of Thoracic Oncology 2017 12, 1654-1663DOI: (10.1016/j.jtho.2017.07.031) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions